Radioisotopes are unstable versions of chemical elements that release excess energy as radiation to reach a more stable state. They are uniquely valuable because this radiation can be easily tracked or used to deliver targeted energy, making them essential for life-saving medical scans, cancer treatments and dating archaeological findings.

Today, radioisotopes are produced primarily through neutron irradiation in nuclear reactors, particle bombardment in cyclotrons or via radionuclide generators. By leveraging the Orbitron as a neutron source, we expect to be able to produce a wide range of radioisotopes faster and at a lower cost than current methods.

We are targeting selling and shipping radioisotope products between 2028 and 2030.

We plan to leverage the Orbitron’s expected neutron-generation capabilities to manufacture specialized medical and power radioisotopes using neutron bombardment rather than traditional fission-based production. By placing target material in close proximity to the device and irradiating it with neutrons, we believe we can produce a broad range of high-value isotopes at scale and at materially lower cost for medical, aerospace, defense, and specialized industrial applications. We intend to use capacity reservation agreements for the isotopes by weight to allow predictability in our sales and easily identify when we need to scale production.

We believe the total addressable market for these products is approximately $23.8 billion across aerospace and defense and pharma sectors according to internal estimates based on generally available government publications, industry reports and trade media. We expect to charge $ to $ per gram, which is typical for radioisotopes.